An FDA panel will meet on April 8 to evaluate Bausch + Lomb's Trulign Toric intraocular lens. The company seeks to have the implantable device approved for treating vision impairment in adult patients who have received cataract surgery.
Bausch + Lomb wins FDA date for vision-correcting implant
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
|Assistant Vice President - Dental Director||